Compare Global X FTSE Southeast Asia ETF (ASEA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Zoetis Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while Zoetis Inc trades at $73.34 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $156.76 |
52-Week Low | $16.86 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $21.43, showing minimal daily movement with a 0.14% gain. Technical indicators signal strong bullish momentum with moving averages unanimously positive and ADX readings above 50 indicating a strong trend. The stock faces immediate resistance at $22 with support clustered around $21. A dividend of $0.41 per share is scheduled for July 2026, providing long-term income potential for investors.
The bullish technical setup suggests potential for near-term upside toward resistance levels, though fundamental analysis is limited without current financial metrics. Investors should monitor upcoming earnings reports for revenue growth and profitability trends. Key risks include market volatility and the company's ability to maintain competitive positioning in its sector.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
